Chemoprevention of cancer by organoselenium compounds.
A major research goal of our laboratories is the development of new organoselenium cancer chemopreventive agents with less toxicity compared to some of the historical selenium compounds, such as sodium selenite. Ideally, such agents would be employed to inhibit tumor development in different organs caused by a variety of chemical carcinogens, particularly those present in the human environment. A series of organoselenium compounds has been synthesized and evaluated for their chemopreventive efficacy in vivo. Parallel to these studies, short-term in vitro and in vivo assays were employed to understand the mechanism of action and to rapidly evaluate their efficacy in eventual long-term preclinical investigations. We demonstrated that one of the most effective of these organoselenium compounds, 1,4-phenylenebis(methylene)selenocyanate (p-XSC, Fig. 1), is capable of inhibiting tumors in the mammary glands, colon, and lung of laboratory animals. Dietary p-XSC inhibited mammary tumor development induced by 7,12-dimethylbenz(a)anthracene (DMBA) during both the initiation and post-initiation phases of carcinogenesis in female CD rats. p-XSC inhibited DMBA-DNA adduct formation in the mammary glands. In collaboration with other laboratories, we demonstrated that p-XSC inhibited thymidine kinase in mammary tumor cell lines derived from both humans and rats. Employing mammary carcinoma cell lines, p-XSC was also shown to inhibit cell growth and induce a dose-dependent increase in cell death by apoptosis. In these assays p-XSC appears superior to selenite and to its sulfur analog, 1,4-phenylenebis(methylene)thiocyanate. Dietary p-XSC decreased colon tumor induction by azoxymethane in F344 rats during both phases of carcinogenesis.(ABSTRACT TRUNCATED AT 250 WORDS)
American Health Foundation, Valhalla, NY 10595, USA.
K
K
el-Bayoumy
P
P
Upadhyaya
Y H
YH
Chae
O S
OS
Sohn
C V
CV
Rao
E
E
Fiala
B S
BS
Reddy
D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000517:prevention & control; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000517:prevention & control; D008325:Mammary Neoplasms, Experimental / Q000517:prevention & control; D051379:Mice; D009374:Neoplasms, Experimental / Q000517:prevention & control; D016566:Organoselenium Compounds / Q000627:therapeutic use*; D051381:Rats
D016588:Anticarcinogenic Agents; D016566:Organoselenium Compounds